Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pemphigoid, Bullous | 2 | 2022 | 108 | 1.400 |
Why?
|
| Scleroderma, Localized | 1 | 2023 | 84 | 0.820 |
Why?
|
| Acitretin | 1 | 2022 | 16 | 0.810 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2022 | 97 | 0.750 |
Why?
|
| Turner Syndrome | 1 | 2021 | 129 | 0.700 |
Why?
|
| Psoriasis | 1 | 2022 | 922 | 0.440 |
Why?
|
| Skin Neoplasms | 5 | 2022 | 5836 | 0.400 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 2 | 2022 | 196 | 0.340 |
Why?
|
| Melanoma | 3 | 2022 | 5695 | 0.310 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2022 | 526 | 0.310 |
Why?
|
| Epidermal Cyst | 1 | 2024 | 63 | 0.230 |
Why?
|
| Skin Diseases | 2 | 2022 | 1083 | 0.220 |
Why?
|
| Students, Medical | 3 | 2021 | 1961 | 0.220 |
Why?
|
| Hamartoma | 1 | 2024 | 235 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 13483 | 0.200 |
Why?
|
| Drug Eruptions | 2 | 2024 | 334 | 0.190 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2023 | 125 | 0.190 |
Why?
|
| Neoplasms | 4 | 2022 | 22336 | 0.180 |
Why?
|
| Nevus, Halo | 1 | 2020 | 5 | 0.180 |
Why?
|
| Biological Therapy | 1 | 2022 | 140 | 0.180 |
Why?
|
| Lymphoma, T-Cell | 1 | 2023 | 308 | 0.180 |
Why?
|
| Decontamination | 1 | 2021 | 73 | 0.180 |
Why?
|
| Myasthenia Gravis | 1 | 2023 | 214 | 0.180 |
Why?
|
| Social Medicine | 1 | 2021 | 64 | 0.180 |
Why?
|
| Myositis | 1 | 2023 | 271 | 0.170 |
Why?
|
| Edema | 1 | 2023 | 763 | 0.160 |
Why?
|
| Students, Dental | 1 | 2020 | 171 | 0.150 |
Why?
|
| Antimalarials | 1 | 2023 | 909 | 0.130 |
Why?
|
| Myocarditis | 1 | 2023 | 802 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2023 | 2425 | 0.110 |
Why?
|
| Longevity | 1 | 2021 | 1085 | 0.110 |
Why?
|
| Piperidines | 1 | 2022 | 1664 | 0.110 |
Why?
|
| Humans | 27 | 2024 | 766019 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 1056 | 0.100 |
Why?
|
| Dermatology | 1 | 2022 | 905 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2021 | 1087 | 0.100 |
Why?
|
| Curriculum | 2 | 2022 | 3784 | 0.090 |
Why?
|
| Retrospective Studies | 10 | 2024 | 81544 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2022 | 3050 | 0.080 |
Why?
|
| Education, Medical | 1 | 2021 | 1744 | 0.080 |
Why?
|
| Skin | 1 | 2022 | 4482 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 4213 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5388 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2021 | 4746 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2022 | 22230 | 0.060 |
Why?
|
| Erythema | 1 | 2024 | 261 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3111 | 0.050 |
Why?
|
| Acrylamides | 1 | 2024 | 260 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3233 | 0.050 |
Why?
|
| Biopsy | 2 | 2024 | 6768 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 26280 | 0.040 |
Why?
|
| Risk Factors | 3 | 2022 | 74837 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2022 | 4408 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 2023 | 429 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2022 | 41677 | 0.040 |
Why?
|
| Aged | 5 | 2024 | 171170 | 0.040 |
Why?
|
| Faculty | 1 | 2022 | 383 | 0.040 |
Why?
|
| Disinfection | 1 | 2021 | 207 | 0.040 |
Why?
|
| Male | 8 | 2024 | 363880 | 0.040 |
Why?
|
| Upper Extremity | 1 | 2023 | 684 | 0.040 |
Why?
|
| Phototherapy | 1 | 2021 | 369 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 5695 | 0.040 |
Why?
|
| Female | 8 | 2024 | 396174 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 1527 | 0.030 |
Why?
|
| Schools, Medical | 1 | 2022 | 882 | 0.030 |
Why?
|
| Ligands | 1 | 2022 | 3274 | 0.030 |
Why?
|
| Aggression | 1 | 2020 | 747 | 0.030 |
Why?
|
| Viral Vaccines | 1 | 2020 | 596 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.030 |
Why?
|
| Age of Onset | 1 | 2020 | 3342 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2022 | 2156 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 59497 | 0.030 |
Why?
|
| Students | 1 | 2022 | 1741 | 0.020 |
Why?
|
| Pandemics | 2 | 2023 | 8724 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2023 | 3068 | 0.020 |
Why?
|
| Middle Aged | 5 | 2024 | 223035 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2020 | 2191 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 3212 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 12975 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 4555 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2021 | 3617 | 0.020 |
Why?
|
| Adult | 4 | 2024 | 223110 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5365 | 0.010 |
Why?
|
| Adolescent | 2 | 2022 | 88808 | 0.010 |
Why?
|
| Quality of Life | 1 | 2024 | 13464 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2024 | 13635 | 0.010 |
Why?
|
| Prognosis | 1 | 2021 | 29905 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 24272 | 0.010 |
Why?
|
| Pregnancy | 1 | 2021 | 30228 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2022 | 65203 | 0.010 |
Why?
|
| Child | 1 | 2022 | 80567 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 59858 | 0.010 |
Why?
|
| United States | 1 | 2021 | 72918 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 168801 | 0.000 |
Why?
|
Concepts
(94)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(60)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_